<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> patients and its clinical implication </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 25 <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL), 2 <z:hpo ids='HP_0011009'>acute</z:hpo> hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AHL</z:e>), 17 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and 7 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P &lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>According to the FAB classification, FLT3-TKD point mutation was found in 3/53 of M(2), 3/40 of M(3), 2/23 of M(5) and 1/2 of M(6) subtypes </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients showed both ITD and TKD mutations </plain></SENT>
<SENT sid="5" pm="."><plain>No FLT3-TDK mutation was found in 25 ALL, 2 AHL, 17 MDS and 7 <z:mp ids='MP_0005481'>CML</z:mp>-BC patients </plain></SENT>
<SENT sid="6" pm="."><plain>Sequence analysis showed that one of the mutations occurred at codon 835 of FLT3 </plain></SENT>
<SENT sid="7" pm="."><plain>The substitution of the first nucleotide T for G of D835, resulted in D835Y, a missense mutation </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of TKD mutations was related neither to age, sex, nor to WBC counts, the marrow blast percentages, and CR rates for induction therapy </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION The incidence of FLT3-TKD(+) is significantly lower than that of ITD mutation </plain></SENT>
<SENT sid="10" pm="."><plain>FLT3-TKD mutations may occur alone or together with ITD mutation </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast to FLT3-ITD mutation, TKD mutations were not associated with <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> or low complete remission rate </plain></SENT>
</text></document>